<DOC>
	<DOCNO>NCT01700270</DOCNO>
	<brief_summary>This multi-center , open-label , single-sequence , crossover , drug-drug interaction ( DDI ) study assess effect CYP1A2 inhibitor , fluvoxamine , PK dovitinib patient advance solid tumor , exclude breast cancer . The purpose study evaluate effect CYP1A2 inhibitor , 100 mg fluvoxamine , PK dovitinib administer dose 300 mg dosing schedule , 5 day on/2 day . The study consist 2 phase : Pharmacokinetic ( PK ) phase clinical treatment phase . The DDI test conduct PK phase . The DDI test ass steady state PK profile dovitinib administer alone presence CYP1A2 inhibitor , fluvoxamine ( AUC 0-24h , AUC 0-72h Cmax parameter ) . During clinical treatment phase patient may continue receive treatment TKI258 disease progression ( assessed RECIST 1.1 ) , unacceptable toxicity , death discontinuation study treatment reason .</brief_summary>
	<brief_title>Pharmacokinetic Drug-drug Interaction Study Dovitinib ( TKI258 ) Patients With Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<mesh_term>Fluvoxamine</mesh_term>
	<criteria>Patients cytopathologically histopathologically confirm diagnosis advance solid tumor , exclude breast cancer progress despite standard therapy standard therapy exist ECOG performance status 0 1 anticipated life expectancy â‰¥3 month Patient must meet protocolspecific laboratory value Patients brain metastases Patients receive expected receive prohibit medication therapy Patients receive CYP1A2 CYP3A inhibitor medication within 5 day prior start study treatment expect receive first 28 day start study treatment Patients receive CYP1A2 CYP3A inducer medication within 30 day prior start study treatment expect receive first 28 day start study treatment Patients actively take antidepressant , benzodiazepine , serotonergic drug , and/or monoamine oxidase inhibitor ( MAOIs ) Patients recover previous anticancer therapy Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption TKI258 Patients concurrent severe and/or uncontrolled concomitant medical condition could compromise participation study Female patient pregnant breastfeed Fertile male woman willing use highly effective method contraception Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>